SecSonar.com

Akebia Therapeutics, Inc. (AKBA)

Akebia Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Akebia Therapeutics, Inc. (AKBA) is a Biotechnology company based in US with a market capitalization of $280.3M. Revenue grew 47.5% year-over-year and the company generated $67.7M in free cash flow. This page tracks AKBA's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 181 employees · IPO Mar 20, 2014

Valuation

Valuation & price

$1.11 · as of May 15, 2026 · -72.3% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

8.60

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$4.01$2.45$0.90Jul 25Dec 25Jul 26Jul 7, 25$3.63Jul 9, 25$3.99Jul 11, 25$3.93Jul 15, 25$3.88Jul 17, 25$3.88Jul 21, 25$3.84Jul 23, 25$4.01Jul 25, 25$3.56Jul 29, 25$3.51Jul 31, 25$3.69Aug 4, 25$3.76Aug 6, 25$3.79Aug 11, 25$3.35Aug 13, 25$3.30Aug 15, 25$3.25Aug 19, 25$3.04Aug 21, 25$3.19Aug 25, 25$3.03Aug 27, 25$3.01Aug 29, 25$3.14Sep 3, 25$3.12Sep 5, 25$2.96Sep 9, 25$3.00Sep 11, 25$2.99Sep 16, 25$2.83Sep 18, 25$2.96Sep 22, 25$2.79Sep 24, 25$2.77Sep 26, 25$2.74Sep 30, 25$2.73Oct 2, 25$2.71Oct 6, 25$2.97Oct 8, 25$2.85Oct 10, 25$2.75Oct 14, 25$2.79Oct 16, 25$2.92Oct 21, 25$3.12Oct 23, 25$2.98Oct 27, 25$3.17Oct 29, 25$2.10Oct 31, 25$2.21Nov 4, 25$2.09Nov 6, 25$2.01Nov 10, 25$1.67Nov 12, 25$1.85Nov 14, 25$1.67Nov 18, 25$1.65Nov 20, 25$1.54Nov 25, 25$1.57Nov 28, 25$1.58Dec 2, 25$1.47Dec 4, 25$1.59Dec 8, 25$1.62Dec 10, 25$1.63Dec 12, 25$1.66Dec 16, 25$1.62Dec 18, 25$1.67Dec 22, 25$1.66Dec 24, 25$1.70Dec 29, 25$1.62Jan 2, 26$1.55Jan 6, 26$1.47Jan 8, 26$1.49Jan 12, 26$1.40Jan 14, 26$1.38Jan 16, 26$1.36Jan 21, 26$1.37Jan 23, 26$1.36Jan 27, 26$1.51Jan 29, 26$1.45Feb 2, 26$1.38Feb 4, 26$1.37Feb 9, 26$1.50Feb 11, 26$1.55Feb 13, 26$1.21Feb 18, 26$1.18Feb 20, 26$1.18Feb 24, 26$1.24Feb 26, 26$1.32Mar 2, 26$1.26Mar 4, 26$1.25Mar 6, 26$1.27Mar 10, 26$1.38Mar 12, 26$1.40Mar 17, 26$1.49Mar 19, 26$1.42Mar 23, 26$1.40Mar 25, 26$1.39Mar 27, 26$1.34Mar 31, 26$1.39Apr 2, 26$1.38Apr 7, 26$1.38Apr 9, 26$1.41Apr 13, 26$1.47Apr 15, 26$1.55Apr 17, 26$1.41Apr 22, 26$1.42Apr 24, 26$1.43Apr 28, 26$1.42Apr 30, 26$1.38May 4, 26$1.50May 6, 26$1.48May 8, 26$1.16May 12, 26$1.18May 14, 26$1.13May 18, 26$1.01May 20, 26$1.01May 22, 26$1.02May 28, 26$1.05Jun 1, 26$1.02Jun 3, 26$0.97Jun 5, 26$0.94Jun 9, 26$0.92Jun 11, 26$0.90Jun 15, 26$0.94Jun 17, 26$1.02Jun 22, 26$1.09Jun 24, 26$1.06Jun 26, 26$1.14Jul 2, 26$1.24
$0.8752-week range$4.01
Loading valuation history…

Fundamentals

Key fundamentals

$280.3M

Market cap

47.5%

Revenue growth (YoY)

83.3%

Gross margin

$67.7M

Free cash flow (USD)

$31.5M

Net debt

21.9%

Share dilution

0/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$1.5MFY 2017$178.0MFY 2018$207.7MFY 2019$335.0MFY 2020$294.6MFY 2021$211.7MFY 2022$292.5MFY 2023$194.6MFY 2024$160.2MFY 2025$236.2M
$1.5M$236.2M

Free cash flow by year

2016 → 2025

FY 2016$55.2MFY 2017$-57.8MFY 2018$-99.1MFY 2019$-264.1MFY 2020$-110.7MFY 2021$-253.0MFY 2022$-73.3MFY 2023$-23.4MFY 2024$-40.7MFY 2025$67.7M
$55.2M$67.7M

Gross margin by year

2021 → 2025

FY 202161.5%FY 202292.3%FY 202361.9%FY 202460.6%FY 202583.3%
61.5%83.3%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventVOICE Trial StoppedJun 30, 2026Filing
  • 8-K eventAnnual Meeting ResultsJun 22, 2026Filing
  • 8-K eventEarnings ReleaseMay 7, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing
  • 8-K eventDirector Resignation and AppointmentApr 1, 2026Filing

Questions

Frequently asked questions

What is Akebia Therapeutics, Inc.'s market cap?

Akebia Therapeutics, Inc. (AKBA) has a market capitalization of $280.3M.

What is AKBA's P/E ratio?

A meaningful P/E ratio is not available for AKBA — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is AKBA's price-to-book (P/B) ratio?

AKBA trades at 8.60 times book value per share.

Are insiders buying AKBA stock?

SEC Form 4 filings show no open-market insider buys at Akebia Therapeutics, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

ACIU

AC Immune S.A.

$281.4M

FENC

Fennec Pharmaceuticals Inc.

$284.4M

STTK

Shattuck Labs, Inc.

$285M

TRDA

Entrada Therapeutics, Inc.

$272.5M

ALT

Altimmune, Inc.

$270.9M

MGNX

MacroGenics, Inc.

$270.5M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.